PharmaCyte Biotech, Inc. — Director's Dealing 2021

Sep 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PharmaCyte Biotech, Inc. (PMCB)
CIK: 0001157075
Period of Report: 2021-08-10

Reporting Person: Waggoner Kenneth L. (Director, Chairman, CEO, Pres and GC)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20600	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$156.00	2022-03-09	Common Stock (3000)		Direct
Stock Option (right to buy)	$83.70	2023-01-01	Common Stock (3000)		Direct
Stock Option (right to buy)	$74.25	2024-03-20	Common Stock (3000)		Direct
Stock Option (right to buy)	$61.20	2025-01-01	Common Stock (3000)		Direct
Stock Option (right to buy)	$10.05	2025-12-31	Common Stock (3000)		Direct

Footnotes

F1: The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").

F2: The exercise price has been adjusted to reflect the Reverse Split.

F3: The option vested in twelve equal monthly installments beginning on January 1, 2021.